Luveltamab tazevibulin,Pegfilgrastim
Sutro Biopharma,Amgen
['stro,002,gm1', 'ovarian', 'stro-002-gm1']
presented by vhio s at #asco23, updated dose expansion data of the stro-002-gm1 ph 1 study show the promise of folr -targeting adc luveltamab tazevibulin in recurrent #ovariancancer. 
Leading translational research to accelerate & advance personalized and targeted therapies against cancer. 
@iCERCA centre